Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Capitalization 39.37B 5.83B P/E ratio 2024 *
45.1x
P/E ratio 2025 * 34.2x
Enterprise value 38.93B 5.76B EV / Sales 2024 *
7x
EV / Sales 2025 * 6.21x
Free-Float
59.05%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.73%
1 week-1.11%
Current month-0.56%
1 month+16.04%
3 months+23.87%
6 months+34.95%
Current year+75.89%
More quotes
1 week
167.50
Extreme 167.5
178.60
1 month
151.60
Extreme 151.6
185.60
Current year
98.50
Extreme 98.5
185.60
1 year
74.30
Extreme 74.3
185.60
3 years
69.90
Extreme 69.9
185.60
5 years
61.70
Extreme 61.7
185.60
10 years
29.25
Extreme 29.25
185.60
More quotes
Director TitleAgeSince
Chief Executive Officer 47 Dec. 31
Director of Finance/CFO 52 23-05-31
Chief Tech/Sci/R&D Officer - 23-02-28
Manager TitleAgeSince
Director/Board Member 55 -
Director/Board Member 65 13-12-31
Director/Board Member 65 15-03-11
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+3.73%-1.11%+123.20%+14.91%5.82B
+0.62%-5.39%+54.87%+278.45%818B
+0.62%-4.53%+30.90%+181.59%582B
+1.36%+0.45%+3.77%-0.87%401B
+1.56%+0.06%+31.81%+83.11%347B
-2.06%-2.57%+5.83%+56.34%293B
-2.55%-7.13%+4.09%-23.22%254B
+0.49%-4.25%+17.20%+54.95%258B
+1.01%-3.02%+13.03%+24.84%238B
+1.67%-2.37%+25.63%+51.18%175B
Average +0.33%-2.99%+31.03%+72.13% 337B
Weighted average by Cap. -0.03%-3.45%+26.97%+119.15%
See all sector performances
2024 *2025 *
Net sales 5.56B 823M 6.15B 909M
Net income 878M 130M 1.16B 171M
Net Debt -445M -65.83M -1.18B -175M
More financial data * Estimated data
Logo ALK-Abelló A/S
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Employees
2,806
Calendar
More about the company
Date Price Change Volume
24-09-09 178.00 kr +3.73% 184,834
24-09-06 171.60 kr +0.53% 165,051
24-09-05 170.70 kr -1.10% 107,693
24-09-04 172.60 kr -1.93% 140,394
24-09-03 176.00 kr -2.22% 138,214

Delayed Quote Nasdaq Copenhagen, September 09, 2024 at 11:20 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
178.00DKK
Average target price
168.60DKK
Spread / Average Target
-5.28%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW